LIVE
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%

Aurobindo Pharma, Bajaj Finance Stocks Surge on Key Developments

By SivamAurobindo Pharma, Bajaj Finance Stocks Surge on Key Developments

Aurobindo Pharma gains US FTC approval for Lannett acquisition, boosting US generics. Bajaj Finance raises Rs 1,455 Cr via NCDs, strengthening its financial position.

Aurobindo Pharma Gains on US FTC Nod; Bajaj Finance Raises Capital

Aurobindo Pharma shares jumped 1.96% to Rs 1471.40 after its arm secured US Federal Trade Commission (FTC) approval for the acquisition of 100% membership interest in Lannett. This move is set to bolster Aurobindo’s presence in the U.S. generics market.

In parallel, Bajaj Finance also moved up 0.55% to Rs 964.40 after its Debenture Allotment Committee approved raising Rs 1,455.40 crore via Non-Convertible Debentures (NCDs).

Aurobindo’s Strategic Expansion

  • The Lannett acquisition aims to diversify Aurobindo into a specialized, high-value therapeutic category.
  • The stock opened at Rs 1461.95 and touched a high of Rs 1480.00 during trading.
  • Trading volume stood at 109274 shares, with the company’s market cap currently at Rs 84658.23 crore.

Bajaj Finance Secures Funding

Bajaj Finance’s capital raise of Rs 1,455.40 crore through NCDs was approved on June 18, 2026, strengthening its financial position.

  • The scrip opened at Rs 951.65 and saw a high of Rs 971.10.
  • A total of 304675 shares were traded for Bajaj Finance.
Home/business/Article